BioPharma Dealmakers March 2016
BioPharma Dealmakers June 2019
BioPharma Dealmakers March 2017
Biopharma Dealmakers | LinkedIn
BioPharma Dealmakers (@bpdealmakers) | Twitter
Download Now: The Ultimate Biopharma Dealmakers Report for Alliances and M&As, Second Edition 2016–2019
BioPharma Dealmakers June 2016
BioPharma Dealmakers (@bpdealmakers) | Twitter
BioPharma Dealmakers on Twitter: "Our November issue is live https://t.co/Ufob1RQH95 Exploring companies and partnering trends in #CNS diseases, specifically #neuroscience and #Alzheimer's disease, and continuing our dealmaking series guide. Complete ...
Biopharma Dealmakers Supplement January
Biopharma Dealmakers | LinkedIn
Volume 14 Issue 3, September 2020
BioPharma Dealmakers
BioPharma Dealmakers on Twitter: "TrioxNano joins our webinar to present location-specific #NanoMachines for #chemotherapy payload delivery: https://t.co/fV75v7hmX4 #oncology… https://t.co/ZlHo6IrW94"
Biopharma Dealmakers | LinkedIn
News & Events
Supporters
Biopharma Dealmakers Feature The Trianni Mouse Platform | Trianni Inc.
Corium to Participate in BioPharma Dealmakers Webcast on New Innovations in Drug Delivery Technology
BioPharma Dealmakers on Twitter: "We cover #cancer #immunotherapy, #antibodies and #regenerative medicine through editorial features and partnering company profiles in our #SeptemberIssue. Take a look! https://t.co/V8Rhgg9CGM… https://t.co/Hijxnq3Tst"
BioPharma Dealmakers Media Kit - Nature Research Partnerships
BioPharma Dealmakers – a new destination for life sciences partnering | Zapnito
BioPharma Dealmakers on Twitter: "Our bumper June 2018 issue is live! With almost 30 profiles from companies focusing on infectious diseases, #fibrosis and #pharma dealmaking, this is our biggest issue of the
Global Cancer Research News & Achievements — TOLREMO therapeutics: Preventing Resistance to Cancer Therapy
PDF) Current deal trends and prospects in therapeutic antibodies
BioPharma Dealmakers March 2017
Publications Archives - Portal Instruments
Nature knows best: fully human antibodies take the therapeutic lead
